Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo says Lilly’s ads use outdated trial data and omit newer Wegovy evidence, giving consumers a misleading picture of GLP-1 drug performance.
- On Tuesday, Novo Nordisk filed suit against Eli Lilly in the U.S. District Court for the District of New Jersey, alleging nationwide advertising campaigns for Zepbound and Mounjaro mislead consumers about GLP-1 drug efficacy.
- Novo alleges Lilly relies on "outdated" clinical trials comparing its highest doses against lower-dose Wegovy, omitting newer 7.2 mg data approved in March showing 47 pounds average weight loss, which Novo says is "clinically consistent" with Zepbound.
- The Zepbound TV commercial has garnered more than 700 million impressions, claiming 50 pounds of weight loss versus 33 pounds on 2.4 mg Wegovy, while Novo calls the footnote disclosing higher doses "ambiguous, confusing, virtually illegible, and wholly inadequate."
- Invoking the Lanham Act, Novo seeks a preliminary injunction and corrective advertising; Kuckelman said Monday that Lilly's ads "leaves them with the inevitable conclusion that Lilly's medicines are superior to Novo's, and that's not accurate."
- Novo argues Lilly has "no basis to make these comparative claims" because no head-to-head trials comparing highest doses exist, and alleges similar deceptive tactics in Mounjaro versus Ozempic ads withholding data on higher doses approved four years ago.
125 Articles
125 Articles
Novo Nordisk's Federal Lawsuit Against Eli Lilly (NYSE: LLY) Reshapes The GLP-1 Investment Landscape
Novo Nordisk has filed a federal lawsuit against Eli Lilly (NYSE: LLY), alleging that Lilly’s nationwide advertising campaigns for Zepbound and Mounjaro relied on outdated clinical data and unfair dose comparisons. The lawsuit claims those advertising tactics were used to assert superiority over Novo’s own flagship GLP-1 therapies, Wegovy and Ozempic, in the fiercely competitive obesity and diabetes drug market. The case raises significant legal…
The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side
Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the wrong direction for Novo. Here is what the stock reaction reveals about who is actually winning this war.
In the United States, the two laboratories do not care about spending on large-scale advertising campaigns on air, small screen, social media and even in stadiums at major national sports competitions.
Coverage Details
Bias Distribution
- 52% of the sources are Center
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
